The “Other” Signaling of Trastuzumab: Antibodies Are Immunocompetent Drugs

This publication has 19 references indexed in Scilit:

• Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
  Journal of Clinical Oncology, 2008
• Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2
  Cancer Research, 2007
• FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab
  Journal of Clinical Oncology, 2007
• Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2
  Clinical Cancer Research, 2004
• Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma
  Journal of Clinical Oncology, 2003
• Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes
  British Journal of Cancer, 2002
• Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
  Blood, 2002
• Untangling the ErbB signalling network
  Nature Reviews Molecular Cell Biology, 2001
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
  Nature Medicine, 2000
• Fc receptors are required in passive and active immunity to melanoma
  Proceedings of the National Academy of Sciences, 1998